Respiratory Infection Observatories on roglobin capsule treatment
Introduction
Upper respiratory infections are common clinical diseases with high rates of morbidity and can be caused by a variety of pathogens, including viruses, bacteria, etc. Among them, bacterial infections or subsequent bacterial infections after viral infections are more common among some patients. As a macrocyclic ester antibiotics, erythroacin has a wide range of applications for the treatment of respiratory bacterial infections. The study observed and analysed the efficacy of respiratory infections in the treatment of erythrin capsules.
Information and methodology
(i) General information
Select [specified time period] [X] cases of upper respiratory infections in visits to [hospital name]. All patients meet the criteria for the diagnosis of upper respiratory infections, including local symptoms such as nose plugs, flue aldicarb, ingesting, coughing and, in some cases, full-body symptoms such as fever, headaches and inefficiency. The age of the patient is [age range], the average age [specific mean age], and the ratio is [X:Y]. Excludes persons who are allergic to erythroacin, those who have severe liver and kidney deficiencies and those who combine other serious underlying diseases.
(ii) Treatment
All patients are given oral treatment for erythrocycin capsules, which are normally used in accordance with the instructions according to the patient ‘ s weight and condition, [the specific dose range], [the number of times the drug is given] per day and [the number of days of the specific course] days. During treatment, a patient with a temperature exceeding 38.5 °C can be given an appropriate level of retortant, avoiding the use of other antibiotics and drugs that may affect the efficacy observation.
(iii) Observation indicators
1. Symptoms improvement
Detailed documentation of changes in local symptoms such as nasal plugs, flue aldicarb, osteoporosis, cough and all-body symptoms such as fever, headaches, inactivity, etc. Symptoms are classified by severity (++++), moderate (+++), mild (++) and no symptoms (-). Observation of the time and improvement of symptoms.
2. Indicators of laboratory inspection
Before and after treatment, patients are subjected to regular blood tests, and changes in indicators such as white cell count and the proportion of neutral particles are observed. In the case of partially coughed patients, stinging examinations are conducted to observe the elimination of pathogens.
3. Adverse effects observation
(b) To monitor closely whether patients suffer from adverse effects such as nausea, vomiting, abdominal pain, diarrhoea and rashes during treatment, and to record their incidence and severity.
(iv) Criteria for determining efficacy
1. Healing: After treatment, all symptoms of the patient have completely disappeared, body temperature has returned to normal, and laboratory tests such as blood routines are normal.
2. Efficiencies: significantly reduced symptoms, loss of whole body symptoms such as fever, significant improvement in local symptoms such as nasal plugs, aldicarb, ingesting, cough, etc., and routine blood tests are generally normal.
3. Effectiveness: symptoms have been reduced, overall and local symptoms have been reduced to a certain extent, and indicators for laboratory examination have improved.
Ineffectiveness: Symptoms have not significantly improved or even increased, and laboratory examination indicators have not changed or deteriorated.
III. Results
(i) Improved symptoms
After treatment, partial symptoms such as nasal plugs, flue aldicarb, ingesting, coughing and whole-body symptoms such as fever, headaches and inactivity have improved to varying degrees. Most patients suffer from abating fever after treatment [a specific number of days], and the body temperature is normal. Symptoms of nasal plugs and fluorine begin to decrease significantly after treatment [specific days 2], while the improvement in osteoporosis and cough symptoms is relatively slow, but at the end of the treatment process most patients suffer from symptoms that disappear or are significantly reduced. This is reflected in the proportion of [X1] per cent of patients with pre-treatment severe symptoms, [X2] per cent of patients with moderate symptoms and [X3] per cent of patients with mild symptoms; after treatment, the proportion of patients with treatment is [remediation] per cent, the proportion of patients with significant effects is [significant] per cent, the proportion of effective patients is [effective] per cent and the proportion of invalid patients is [ineffective] per cent.
(ii) Changes in laboratory inspection indicators
Before treatment, there were [specified 1] cases of increased white cell count and/or a higher percentage of neutral particle cells. After treatment, a review of blood patterns shows that the white cell count and the neutral particle-cell ratio of most patients have returned to normal, with a normal rate of [white cell normal] per cent and a normal rate of [neutral particle normal] per cent. The haze examination showed that [specified number 2] cases of patients who had growth before treatment and the rate of elimination of post-treatment pathogens was [proportion of pathogen elimination] per cent.
(iii) Cases of adverse effects
In the course of treatment, there were instances of adverse reactions by [the number of adverse effects] patients, with an incidence of adverse effects of [the incidence of adverse effects] per cent. Of these, there were cases of nausea, vomiting [specified number of persons 3], abdominal pain, diarrhoea [specific number 4] and rash [specified number 5]. Symptoms of adverse effects are generally mild and are self-mitigated after treatment or without special treatment, without prejudice to the continuation of treatment.
IV. Discussion
(i) Treatment mechanisms for roacin capsules
erythroacin is an antibiotic of the Great Ringed ester, and its mechanism of action is mainly antibacterial by inhibiting the synthesis of bacterial proteins through a combination of 50 S-based bacterial nuclei. Better antibacterial activity is observed for pathogens common to upper respiratory infections, such as pneumocococcus, soluble streptococcus and haemophilus influenzae. In this study, changes in symptoms and laboratory-testing indicators show that erythroacin capsules can be effective in inhibiting pathogens and mitigating inflammatory reactions, thus mitigating symptoms of upper respiratory infections.
(ii) Effects analysis
In terms of signs of improvement, erythrocycin capsules have had a significant effect in mitigating the symptoms of fever, nose plugs and aldicarb. This may be due to the fact that drugs inhibit the growth and reproduction of pathogens and reduce the incentive of pathogens and their toxins to organisms, while reducing local inflammation response. In terms of laboratory-testing indicators, the normalization of white-cell count and neutral particle-cell ratio, as well as the eradication rate of the stinging pathogen, have further confirmed the antibacterial effects of the erythromic capsule. High post-treatment cure rates and efficiency indicate that erythroacin capsules are effective drugs for the treatment of upper respiratory infections.
(iii) Analysis of adverse effects
In this study, the incidence of adverse effects in erythrocycin capsule therapy is low and the symptoms are low. The gastrointestinal reaction, such as nausea, vomiting, abdominal pain and diarrhoea, is a common adverse reaction to macrocyclic ester antibiotics and may be associated with drug irritant gastrointestinal mucous membranes. An allergies such as rashes are relatively low. The occurrence of adverse reactions suggests that, in clinical applications, while erythrocycin capsules are relatively safe, there is still a need to pay attention to patients ‘ drug responses, especially those with special circumstances such as a history of gastrointestinal diseases.
Conclusions
This study shows that respiratory infections in roacin capsule treatment have better therapeutic effects, can effectively mitigate the symptoms of patients, improve laboratory testing indicators and have a low incidence of adverse effects. In the clinical treatment of respiratory infections, erythroacin capsules are an optional and effective drug, but in their use, care is taken to observe the adverse reactions of patients and to ensure their safety. At the same time, treatment for upper respiratory infections should be further tailored to the specific circumstances of the patient, such as the type of pathogen, the severity of the disease, the rational choice of the drug and the development of treatment programmes.
